NCT05879458View on ClinicalTrials.gov

Ritlecitinib in CTCL

PHASE2TerminatedINTERVENTIONAL
Enrollment

7

Participants

Timeline

Start Date

May 17, 2023

Primary Completion Date

June 25, 2025

Study Completion Date

June 25, 2025

Conditions
CTCLMycosis FungoidesSezary Syndrome
Interventions
DRUG

Ritlecitinib

200 mg QD for 8 weeks followed by 100 mg for 16 weeks

Trial Locations (1)

10029

Icahn School of Medicine at Mount Sinai, New York

Sponsors

Collaborators (1)

Pfizer
All Listed Sponsors
collaborator

Pfizer

INDUSTRY

lead

Icahn School of Medicine at Mount Sinai

OTHER

NCT05879458 - Ritlecitinib in CTCL | Biotech Hunter | Biotech Hunter